Welcome to our dedicated page for Evotec SEC filings (Ticker: EVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revenue from milestone payments, shared R&D fees, and biologics manufacturing makes Evotec’s disclosures anything but straightforward. Sorting out when a partner payment is recognized or how biologics capacity expansions hit cash flow can take hours. That’s why this page opens every Evotec insider trading Form 4 transactions and each Evotec quarterly earnings report 10-Q filing the moment they post to EDGAR, then runs them through Stock Titan’s AI for instant clarity.
Need the highlights from a 300-page annual report? Our engine delivers Evotec annual report 10-K simplified (Form 20-F) notes on partnership economics, while "understanding Evotec SEC documents with AI" maps footnotes to the exact pipeline assets they cover. For event-driven traders, Evotec 8-K material events explained pinpoints new collaboration announcements; long-only holders track dilution risk via Evotec executive stock transactions Form 4 and Evotec Form 4 insider transactions real-time alerts. If you follow governance, the Evotec proxy statement executive compensation section compares R&D bonuses to peer CDMOs in minutes.
Whether you’re scanning short-term catalysts or building a long-term DCF, you’ll find every filing type here—20-F, 6-K, F-3, Schedule 13D/G—plus concise AI-powered summaries that turn accounting language into accessible insights. Use our practical filters to:
- Monitor milestone revenue timing with Evotec earnings report filing analysis
- Contrast quarter-over-quarter spend on Just-Evotec Biologics projects
- Flag material partner amendments before market open
Evotec SE filed a Form 6-K announcing that its management resolved on November 06, 2025 to implement a share repurchase program. The company states that the program is described in Exhibit 99.1, an announcement made pursuant to Article 5(1)(a) of Regulation (EU) No. 596/2014 and Article 2(1) of Delegated Regulation (EU) No. 2016/1052.
This is an administrative disclosure indicating the company’s decision to buy back shares, with specific terms set out in the accompanying exhibit.
Evotec SE reported it has signed a final agreement with Sandoz. According to the company’s announcement, the transaction could result in payments potentially over US$ 650 m, plus royalties tied to a portfolio of up to 10 biosimilar molecules.
The update was furnished via a Form 6-K alongside a press release. The disclosure highlights the scale of the collaboration and the royalty-bearing structure on a multi-asset biosimilar portfolio, indicating a broad, long-term commercial framework with Sandoz.
FAQ
What is the current stock price of Evotec (EVO)?
What is the market cap of Evotec (EVO)?
